Albert Bourla, Chairman and Chief Executive Officer at Pfizer, shared a post on LinkedIn:

“Today, I shared Pfizer’s 2024 Q1 financial results. We had a solid start to the year, and I’m proud that in the first three months, we reached more than 119 million patients* with our medicines and vaccines. Additionally, we have made notable progress on our five strategic priorities. Here are some highlights:

– We are continuing to build world-class oncology leadership. Just this week, the FDA recently approved our treatment for metastatic cervical cancer, which has demonstrated a 30% reduction in the risk of death compared with chemotherapy. We also recently received the ‘Outstanding Achievement Award for Service to Cancer Science and Medicine’ from the American Association for Cancer Research, a testament to the incredible work of our Pfizer Oncology team.

– Our hematology program is a priority area of focus, and we’re committed to advancing innovative solutions. The FDA recently approved our first-ever gene therapy to treat hemophilia B, an incredible accomplishment that is the result of a multi-year effort to help people living with this rare disease. We also expect regulatory approval before year’s end for the first potential once-weekly subcutaneous treatment for hemophilia B and the first potential treatment that can be delivered as a flat dose for both hemophilia A and B.

– We recently reported positive results from our Phase 3 trial evaluating our RSV vaccine for adults aged 18 to 59. The trial met its primary endpoints, and we intend to submit these data to regulatory agencies. Our vaccine is on track to potentially be the first and only RSV vaccine for adults 18+, providing a possible solution to people of many ages to protect themselves from this respiratory disease.

My deep thanks to my amazing Pfizer colleagues, who inspire me every day with their commitment to improving healthcare for everyone. We come from all corners of the globe, but we are united by our common purpose to make the world a better place for us, our children and the generations to come.

*Patient counts are estimates derived from multiple data sources.”

Read further.
Source: Albert Bourla/LinkedIn